Release Date: October 31, 2025
Expiration Date: October 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned ophthalmologists and optometrists to discuss managing ocular toxicities associated with select antibody-drug conjugates, monoclonal antibodies, and selective estrogen receptor degraders to optimize patient outcomes and to improve collaborative, multidisciplinary care, including shared decision-making, that enables the cancer care team to monitor and manage the various ocular toxicities associated with these therapies.
This educational activity is an archive of the live symposium held on September 27, 2025.
Target Audience
This educational activity is directed toward ophthalmologists, oncologists, optometrists, and other health care professionals who would be involved in the management of patients with ocular toxicities secondary to cancer treatment.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review clinical trial data on the efficacy and safety of oncology drugs associated with ocular toxicities
- Outline approaches for early detection, monitoring, and management of ocular adverse events in patients receiving targeted therapies
- Coordinate multidisciplinary strategies that support collaborative care between oncology and ophthalmology teams in managing ocular toxicities
Basil Williams, MD
Associate Professor of Clinical Ophthalmology
University of Miami Health System
Miami, FL
Disclosures: Advisor: AbbVie, Alcon, Alimera, Astellas, DORC, EyePoint, Genentech, Immunocore, Ocular Therapeutix, Regeneron; Ownership interests in privately held companies: Lumata Health
Maura Di Nicola, MD
Assistant Professor of Ophthalmology
Bascom Palmer Eye Institute
Miami Miller School of Medicine
Miami, FL
Disclosures: Advisor, Consultant, Speaker,
Honoraria Recipient: AbbVie, SpringWorks Therapeutics
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
